Comparison of Bacterial Contamination Rates Between Isolation and Non-isolation Rooms
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is to determine if medication cabinets located outside of isolation rooms in hospitals and their contents, particularly medications and the delivery folders are at a higher risk of having harmful bacteria on them.
| Condition |
|---|
|
Methicillin-Resistant Staphylococcus Aureus |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Comparison of Contamination Rates of Medication Storage Cabinets Between Isolation and Non-isolation Rooms With Methicillin-resistant Staphylococcus Aureus (MRSA) |
- Presence of MRSA colonization [ Time Frame: Hospital stay, an expected average of 14 days ] [ Designated as safety issue: Yes ]Swabbing of four areas of the medication cabinet will be performed (keypad, handle, medication folder and a medication). A Semi-quantitative sampling technique will be used to collect the samples. A sterile saline moistened sterile cotton tip swab will be used to swab the specified areas. The swabs will then be used to inoculate sheep blood agar plates in 4 quadrants. The plates will be incubated for 48 hours. The number of quadrants with growth will be identified. Individual colonies will be removed from the plate with an inoculation loop, then streaked onto a second sheep blood agar plate. The second plates will be incubated for 48 hours. The colonies will then be run through standard identification tests to determine if the colonies are MRSA or not. A comparison will be made between non-isolation and isolation rooms.
- Quantification of MRSA colonization [ Time Frame: Hospital stay, an expected average of 14 days ] [ Designated as safety issue: Yes ]Swabbing of four areas of the medication cabinet will be performed (keypad, handle, medication folder and a medication). A Semi-quantitative sampling technique will be used to collect the samples. A sterile saline moistened sterile cotton tip swab will be used to swab the specified areas. The swabs will then be used to inoculate sheep blood agar plates in 4 quadrants. The plates will be incubated for 48 hours. The number of quadrants with growth will be identified. A comparison between the sites of swabbing will be performed.
- Presence of other bacterial colonization [ Time Frame: Hospital stay, an expected average of 14 days ] [ Designated as safety issue: Yes ]Swabbing of four areas of the medication cabinet will be performed (keypad, handle, medication folder and a medication). A Semi-quantitative sampling technique will be used to collect the samples. A sterile saline moistened sterile cotton tip swab will be used to swab the specified areas. The swabs will then be used to inoculate sheep blood agar plates in 4 quadrants. The plates will be incubated for 48 hours. The number of quadrants with growth will be identified. Individual colonies will be removed from the plate with an inoculation loop, then streaked onto a second sheep blood agar plate. The second plates will be incubated for 48 hours. The colonies will be categorized as gram negative, gram positive catalase negative, Gram positive coagulase negative Staphylococcus species or methicillin-sensitive Staphylococcus aureus. This will serve as a baseline epidemiology of the hospital and generate other possible hypotheses.
- Correlation between MRSA and active infection or colonization of patient [ Time Frame: Hospital stay, an expected average of 14 days ] [ Designated as safety issue: No ]The patient from the same time frame in the rooms sampled and positive for MRSA colonization will be reviewed to determine if they had active infection or were previously colonized.
- Correlation between colonization of other positive organisms and active infection or colonization of patient [ Time Frame: Hospital stay, an expected average of 14 days ] [ Designated as safety issue: No ]The patient from the same time frame in the rooms sampled and positive for non-MRSA colonization will be reviewed to determine if they had active infection or were previously colonized.
| Estimated Enrollment: | 400 |
| Study Start Date: | August 2012 |
| Estimated Study Completion Date: | June 2013 |
| Estimated Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Isolation Rooms for MRSA
Rooms that currently have a patient in them that are in isolation status due to MRSA
|
|
Non-isolation rooms
Rooms that have not been occupied by a patient in isolation due to MRSA for 14 days
|
Detailed Description:
Studies show high touch areas maybe contaminated with organisms such as Methicillin—resistant Staphylococcus aureus(MRSA) and vancomycin-resistant enterococci. MRSA can live on hospital surfaces for 9-14 days. Patients in rooms that were previously MRSA isolation rooms are at higher risk for developing a hospital-acquired infection.
This study is to determine if medication cabinets located outside of MRSA isolation rooms and their contents, particularly medications and the pharmacy delivery folders are at a higher risk of having MRSA colonization on them. This study will use conventional methods to determine if MRSA colonization is present and compare results between non-isolation and isolation rooms. This will evaluate if alternate measures for the reduction of MRSA colonization are needed for the MRSA isolation rooms in regards to medication delivery and storage.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Inaptients at an academic medical center
Inclusion Criteria:
- Patient rooms with isolation status for MRSA
- Patient rooms without isolation status for MRSA for 14 days
Exclusion Criteria:
- Rooms without medication cabinets directly outside the room
Contacts and Locations| United States, West Virginia | |
| West Virginia University Hospitals | Recruiting |
| Morgantown, West Virginia, United States, 26506 | |
| Contact: Michael A Sweet, Pharm.D. 304-598-4000 ext 73201 sweetm@wvuhealthcare.com | |
| Principal Investigator: Michael A Sweet, PharmD | |
| Sub-Investigator: Holly Kirk, PharmD | |
| Sub-Investigator: Frank E Briggs, PharmD, MPH | |
| Sub-Investigator: Rodney B Turner, PharmD | |
| Sub-Investigator: Rocco LaSala, MD | |
| Sub-Investigator: Douglas Slain, PharmD | |
| Sub-Investigator: Rashida Khakoo, MD | |
More Information
Publications:
| Responsible Party: | Michael Sweet, Pharmacy Clinical Specialist - Quality Outcomes, West Virginia University |
| ClinicalTrials.gov Identifier: | NCT01671358 History of Changes |
| Other Study ID Numbers: | WVU-00010 |
| Study First Received: | August 16, 2012 |
| Last Updated: | August 20, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by West Virginia University:
|
MRSA Contamination Isolation |
Additional relevant MeSH terms:
|
Staphylococcal Infections Gram-Positive Bacterial Infections Bacterial Infections |
ClinicalTrials.gov processed this record on June 18, 2013